SARS-2 Vaccine Resistance

We tried incubating these pseudotype particles with BAM-line infamab, which is one of the first monoclonals that was released under emergency use for SARS-2. And we were able to get serum from individuals that had received two doses of either the Moderna or Pfizer vaccine. We combined those sera with our pseudotypes and tried to infect our ACE2 expressing cells. And what we saw was that the full-length spike was nicely inhibited by serum from people who had received the vaccines. But again, the costa to chimeric spike was notably reduced in its ability to be inhibited by the virus. So it seemed to be somewhat resistant to at least